Bentracimab
# Bentracimab

Bentracimab is a monoclonal antibody medication which has been shown in phase one and two clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a $P2Y_{12}$ inhibitor and is sold under the brand name Brilinta among others). It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor. It is not commercially available.

